Mr. Stephen Van Deventer reports

PREVECEUTICAL CLOSES THIRD TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Preveceutical Medical Inc., further to its news releases dated June 12, 2026, May 12, 2026, and April 22, 2026, has closed a third tranche of its previously announced non-brokered private placement, which third tranche consisted of the issuance of eight million units of the company at a price of 2.5 cents per unit for gross aggregate proceeds of $200,000. The company closed an initial tranche on May 12, 2026, consisting of the issuance of 13.6 million units for gross proceeds of $340,000, and a second tranche on June 12, 2026, consisting of the issuance of 9.8 million units for gross proceeds of $245,000. The company has received aggregate proceeds of $785,000 from the initial tranche, the second tranche and the third tranche. Preveceutical intends to close further tranches for the remainder of the offering in the next four weeks.

Each unit comprises one common share in the capital of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of five cents per warrant share for a period of two years from the closing of the second tranche, subject to an acceleration right, whereby the expiry date of the warrants may be accelerated if the daily closing price of the shares equals or exceeds 10 cents or greater on the Canadian Securities Exchange (or such other recognized securities exchange on which the shares may then trade) for a minimum of 10 consecutive trading days, in which event the company may accelerate the expiry of the warrants by giving notice via news release and, in such case, all of the then unexercised warrants will expire on the 30th day after the date on which the news release is disseminated.

In connection with the third tranche closing, the company paid an advisory commission fee of $19,600 to one eligible finder and issued 784,000 advisory commission warrants. The advisory commission warrants are exercisable into one additional share at an exercise price of five cents per share for two years from the second tranche closing, subject to the acceleration right.

The company intends to use the aggregate gross proceeds of the third tranche to pay outstanding payables, for operating expenses and for general working capital purposes.

All securities issued in relation to the third tranche are subject to a hold period expiring four months and one day after the third tranche closing, in accordance with applicable securities laws.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.